Dr. Reddy's Laboratories Ltd. reported strong earnings in the first quarter of fiscal 2024, buoyed by an impressive run in the US amid continued gains from generic (g) Revlimid (lenalidomide).
Dr Reddy’s Q1 Talking Points: Solid US Gains, Mark Cuban Cost Plus Drug Co, China
Strong Fiscal First Quarter For Dr Reddy's
A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?
